597 related articles for article (PubMed ID: 24356549)
1. Hepatorenal syndrome and novel advances in its management.
Fabrizi F; Aghemo A; Messa P
Kidney Blood Press Res; 2013; 37(6):588-601. PubMed ID: 24356549
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the management of hepato-renal syndrome (HRS).
Fabrizi F; Martin P; Messa P
Acta Clin Belg; 2007; 62 Suppl 2():393-6. PubMed ID: 18284007
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
6. Hepatorenal syndrome.
Angeli P; Morando F; Cavallin M; Piano S
Contrib Nephrol; 2011; 174():46-55. PubMed ID: 21921608
[TBL] [Abstract][Full Text] [Related]
7. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.
Fagundes C; Ginès P
Am J Kidney Dis; 2012 Jun; 59(6):874-85. PubMed ID: 22480795
[TBL] [Abstract][Full Text] [Related]
8. Hepatorenal syndrome.
Biswas KD; Jain AK
Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
[TBL] [Abstract][Full Text] [Related]
9. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
10. Results of pretransplant treatment of hepatorenal syndrome with terlipressin.
Solà E; Cárdenas A; Ginès P
Curr Opin Organ Transplant; 2013 Jun; 18(3):265-70. PubMed ID: 23652609
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
12. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
14. The management of hepatorenal syndrome.
Carl DE; Sanyal A
Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in our understanding of hepatorenal syndrome.
Wong F
Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):382-91. PubMed ID: 22614754
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.
Sridharan K; Sivaramakrishnan G
J Gen Intern Med; 2018 Jan; 33(1):97-102. PubMed ID: 28924736
[TBL] [Abstract][Full Text] [Related]
17. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
18. Hepatorenal syndrome.
Guevara M; Ginès P
Dig Dis; 2005; 23(1):47-55. PubMed ID: 15920325
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome.
Krag A; Møller S; Henriksen JH; Holstein-Rathlou NH; Larsen FS; Bendtsen F
Hepatology; 2007 Dec; 46(6):1863-71. PubMed ID: 18027874
[TBL] [Abstract][Full Text] [Related]
20. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
